Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline Review, H1 2020’, provides an overview of the Attention Deficit Hyperactivity Disorder (ADHD) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Attention Deficit Hyperactivity Disorder (ADHD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Attention Deficit Hyperactivity Disorder (ADHD)

– The report reviews pipeline therapeutics for Attention Deficit Hyperactivity Disorder (ADHD) by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Attention Deficit Hyperactivity Disorder (ADHD) therapeutics and enlists all their major and minor projects

– The report assesses Attention Deficit Hyperactivity Disorder (ADHD) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Attention Deficit Hyperactivity Disorder (ADHD)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Attention Deficit Hyperactivity Disorder (ADHD)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Attention Deficit Hyperactivity Disorder (ADHD) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4P-Pharma SAS

AgoneX Biopharmaceuticals Inc

Altus Formulation Inc

Amarantus Bioscience Holdings Inc

Arbor Pharmaceuticals LLC

Attentive Therapeutics Inc

Avekshan LLC

BCWorld Pharm Co Ltd

Boston Pharmaceuticals Inc

Cennerv Pharma (S) Pte Ltd

Cingulate Therapeutics LLC

Collegium Pharmaceutical Inc

Curemark LLC

DD Therapeutics LLC

DURECT Corp

Eli Lilly and Co

EncepHeal Therapeutics Inc

Ensysce Biosciences Inc

Highland Therapeutics Inc

INVENT Pharmaceuticals Inc

Kashiv BioSciences LLC

KemPharm Inc

Limoxifen BV

Mind Medicine Inc

NLS Pharma Group

Noven Pharmaceuticals Inc

Oryzon Genomics SA

Otsuka Holdings Co Ltd

Otsuka Pharmaceutical Co Ltd

P2D Inc

RespireRx Pharmaceuticals Inc

Reviva Pharmaceuticals Inc

Seropeutics LLC

Shenox Pharmaceuticals LLC

Shionogi & Co Ltd

SK Biopharmaceuticals Co Ltd

Sunovion Pharmaceuticals Inc

Supernus Pharmaceuticals Inc

Suven Life Sciences Ltd

Taho Pharmaceuticals Ltd

Terran Biosciences Inc

Tris Pharma Inc

Vallon Pharmaceuticals Inc

Yuyu Pharma Inc

Table of Contents

Table of Contents

Introduction

Attention Deficit Hyperactivity Disorder (ADHD) – Overview

Attention Deficit Hyperactivity Disorder (ADHD) – Therapeutics Development

Attention Deficit Hyperactivity Disorder (ADHD) – Therapeutics Assessment

Attention Deficit Hyperactivity Disorder (ADHD) – Companies Involved in Therapeutics Development

Attention Deficit Hyperactivity Disorder (ADHD) – Drug Profiles

Attention Deficit Hyperactivity Disorder (ADHD) – Dormant Projects

Attention Deficit Hyperactivity Disorder (ADHD) – Discontinued Products

Attention Deficit Hyperactivity Disorder (ADHD) – Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by 4P-Pharma SAS, H1 2020

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by AgoneX Biopharmaceuticals Inc, H1 2020

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Altus Formulation Inc, H1 2020

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Amarantus Bioscience Holdings Inc, H1 2020

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Arbor Pharmaceuticals LLC, H1 2020

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Attentive Therapeutics Inc, H1 2020

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Avekshan LLC, H1 2020

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by BCWorld Pharm Co Ltd, H1 2020

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Boston Pharmaceuticals Inc, H1 2020

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Cennerv Pharma (S) Pte Ltd, H1 2020

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Cingulate Therapeutics LLC, H1 2020

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Collegium Pharmaceutical Inc, H1 2020

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Curemark LLC, H1 2020

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by DD Therapeutics LLC, H1 2020

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by DURECT Corp, H1 2020

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Eli Lilly and Co, H1 2020

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by EncepHeal Therapeutics Inc, H1 2020

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Ensysce Biosciences Inc, H1 2020

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Highland Therapeutics Inc, H1 2020

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by INVENT Pharmaceuticals Inc, H1 2020

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Kashiv BioSciences LLC, H1 2020

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by KemPharm Inc, H1 2020

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Limoxifen BV, H1 2020

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Mind Medicine Inc, H1 2020

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by NLS Pharma Group, H1 2020

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Noven Pharmaceuticals Inc, H1 2020

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Oryzon Genomics SA, H1 2020

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Otsuka Holdings Co Ltd, H1 2020

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Otsuka Pharmaceutical Co Ltd, H1 2020

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by P2D Inc, H1 2020

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by RespireRx Pharmaceuticals Inc, H1 2020

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Reviva Pharmaceuticals Inc, H1 2020

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Seropeutics LLC, H1 2020

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Shenox Pharmaceuticals LLC, H1 2020

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Shionogi & Co Ltd, H1 2020

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by SK Biopharmaceuticals Co Ltd, H1 2020

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Sunovion Pharmaceuticals Inc, H1 2020

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Supernus Pharmaceuticals Inc, H1 2020

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Suven Life Sciences Ltd, H1 2020

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Taho Pharmaceuticals Ltd, H1 2020

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Terran Biosciences Inc, H1 2020

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Tris Pharma Inc, H1 2020

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Vallon Pharmaceuticals Inc, H1 2020

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Yuyu Pharma Inc, H1 2020

Attention Deficit Hyperactivity Disorder (ADHD) – Dormant Projects, H1 2020

Attention Deficit Hyperactivity Disorder (ADHD) – Dormant Projects, H1 2020 (Contd..1), H1 2020

Attention Deficit Hyperactivity Disorder (ADHD) – Dormant Projects, H1 2020 (Contd..2), H1 2020

Attention Deficit Hyperactivity Disorder (ADHD) – Dormant Projects, H1 2020 (Contd..3), H1 2020

Attention Deficit Hyperactivity Disorder (ADHD) – Dormant Projects, H1 2020 (Contd..4), H1 2020

Attention Deficit Hyperactivity Disorder (ADHD) – Discontinued Products, H1 2020

List of Figures

List of Figures

Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports